These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 31974170)

  • 1. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.
    Pei S; Pollyea DA; Gustafson A; Stevens BM; Minhajuddin M; Fu R; Riemondy KA; Gillen AE; Sheridan RM; Kim J; Costello JC; Amaya ML; Inguva A; Winters A; Ye H; Krug A; Jones CL; Adane B; Khan N; Ponder J; Schowinsky J; Abbott D; Hammes A; Myers JR; Ashton JM; Nemkov T; D'Alessandro A; Gutman JA; Ramsey HE; Savona MR; Smith CA; Jordan CT
    Cancer Discov; 2020 Apr; 10(4):536-551. PubMed ID: 31974170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective eradication of venetoclax-resistant monocytic acute myeloid leukemia with iron oxide nanozymes.
    Zhang S; Lou S; Bian W; Liu J; Wang R; Wang Y; Zhao Y; Zou X; Jin D; Liang Y; Sun J; Liu L
    Biochem Biophys Res Commun; 2024 Jul; 719():150117. PubMed ID: 38761635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine.
    Tambe M; Unterberger S; Kriegbaum MC; Vänttinen I; Olgac EJ; Vähä-Koskela M; Kontro M; Wennerberg K; Heckman CA
    Cell Death Dis; 2024 Oct; 15(10):750. PubMed ID: 39414773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia.
    Nwosu GO; Ross DM; Powell JA; Pitson SM
    Cell Death Dis; 2024 Jun; 15(6):413. PubMed ID: 38866760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
    Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax in AML: Where We Are and Where We Are Headed.
    Pollyea DA
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S25-S26. PubMed ID: 32862856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.
    Shahswar R; Ganser A
    Expert Rev Hematol; 2024 Oct; 17(10):723-739. PubMed ID: 39246164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
    Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
    Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Murthy GSG; Saliba AN; Szabo A; Harrington A; Abedin S; Carlson K; Michaelis L; Runaas L; Baim A; Hinman A; Maldonado-Schmidt S; Venkatachalam A; Flatten KS; Peterson KL; Schneider PA; Litzow M; Kaufmann SH; Atallah E
    Haematologica; 2024 Sep; 109(9):2864-2872. PubMed ID: 38572562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.
    Weidenauer K; Schmidt C; Rohde C; Pauli C; Blank MF; Heid D; Waclawiczek A; Corbacioglu A; Göllner S; Lotze M; Vierbaum L; Renders S; Krijgsveld J; Raffel S; Sauer T; Trumpp A; Pabst C; Müller-Tidow C; Janssen M
    Leukemia; 2023 Aug; 37(8):1611-1625. PubMed ID: 37414921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can we selectively target AML stem cells?
    Jordan CT
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
    Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
    Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
    Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
    Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia.
    Makowka P; Stolp V; Stoschek K; Serve H
    Biol Chem; 2021 Nov; 402(12):1547-1564. PubMed ID: 34700366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting NF-κB-dependent alkaliptosis for the treatment of venetoclax-resistant acute myeloid leukemia cells.
    Zhu S; Liu J; Kang R; Yang M; Tang D
    Biochem Biophys Res Commun; 2021 Jul; 562():55-61. PubMed ID: 34034094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.